您当前的位置:
(+)- Corydaline (Synonyms: 紫堇碱; (+)-Corydaline; Corydalin)
目录号: PC13678 纯度: ≥98%
CAS No. :518-69-4
商品编号 规格 价格 会员价 是否有货 数量
PC13678-20mg 20mg ¥3449.60 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
(+)- Corydaline
中文别名
延胡索碱甲;2,3,9.10-四甲氧基-13Α-甲基-13ΑΒ-小檗因;延胡索碱;紫堇碱;紫菫鹼;(+)-紫堇碱,延胡索甲素;延胡索碱(紫堇块茎碱);延胡索甲素;WAKO036-14971榛子蛋白质标准品;延胡索甲素(标准品);延胡索甲素(紫堇碱);延胡索甲素对照品;延胡索碱甲Corydaline;紫堇;紫堇碱:(延胡索甲素:Corydaline);紫堇碱标准品;紫堇灵 Corydaline;延胡索甲素(紫堇碱,延胡索碱,(+)-紫堇碱,D-紫堇碱);延胡索甲素,紫堇碱;紫堇碱,延胡索碱甲,延胡索甲素
英文名称
(+)- Corydaline
英文别名
Corydaline;(13s-e)-thyl;2,3,9,10-tetramethoxy-13-alpha-methyl-13a-beta-berbin;2,3,9,10-tetramethoxy-13-methyl-berbin;6h-dibenzo(a,g)quinolizine,5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-13-me;corydalin;(+) CORYDALINE;CORYDALINE, (+);(+)- Corydaline;(13S,13aR)-2,3,9,10-tetramethoxy-13-methyl-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline;Berbine,2,3,9,10-tetramethoxy-13-methyl;d-Corydalin;(+)-Corydaline;d-Corydaline;08N392L8VX
Cas No.
518-69-4
分子式
C22H27NO4
分子量
369.45
包装储存
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
生物活性

Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 μM. Corydaline is a μ-opioid receptor (Ki of 1.23 μM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 μM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities.

性状

Solid

IC50 & Target[1][2]

AChE

 

μ Opioid Receptor/MOR

 

体外研究(In Vitro)

Corydaline (12.5-50 μM; 24 hours) treatment inhibits EV71 replication by suppressing the COX-2 expression and the phosphorylation of JNK MAPK and P38 MAPK but not ERK MAPK 体外研究.
Corydaline could inhibit the viral RNA synthesis in a dose dependent manner.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line: Vero cells infected with EV71
Concentration: 12.5 μM, 25 μM, 50 μM
Incubation Time: 24 hours
Result: Reduced the phosphorylation of P38 MAPK and JNK MAPK and the expression of COX-2.
体内研究(In Vivo)

Corydaline (10 mg/kg; subcutaneous administration; once) treatment shows antinociceptive effects in mice by significantly inhibiting the writhing behavior.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male CD1 mice (30-35 g, 7-8 weeks old) injected with acetic acid
Dosage: 10 mg/kg
Administration: Subcutaneous administration; once
Result: Showed antinociceptive effects in mice.
运输条件

Room temperature or refrigerated transportation.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
结构分类
来源
参考文献
溶解度数据
体外研究: 

DMSO : 33.33 mg/mL (90.22 mM; Need ultrasonic)

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.7067 mL 13.5336 mL 27.0673 mL
5 mM 0.5413 mL 2.7067 mL 5.4135 mL
10 mM 0.2707 mL 1.3534 mL 2.7067 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (6.77 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2